ESR1 and metastatic neoplasm: The effects of these endocrine therapies, however, are limited in many patients (about 50%) with metastatic disease who develop acquired resistance, leading in turn to endocrine insensitivity and the increased migration of differentiated epithelial cancer cells.[3] ER status is the main predictor of patients’ response to endocrine therapy.[4]